MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
2022年10月5日 - 01:00AM
ビジネスワイヤ(英語)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
survival outcomes for patients with cancer, today announced the
appointment of Nathalie Corvaïa, Ph.D., as Chief Scientific
Officer. Dr. Corvaïa brings more than 20 years of experience
leading drug discovery and development programs in oncology and
guiding the advancement of product candidates into the clinic. She
will oversee MaaT Pharma’s non-clinical research and development
strategies as well as the Company’s proprietary, AI-based MET drug
design and development platform, gutPrint®.
“Nathalie has an impressive depth of experience and track record
in early-stage research and development of drug candidates in
immune-mediated diseases. She joins us as we are generating
exciting preclinical results for our first co-cultured candidate
aimed at improving clinical responses in patients with solid tumors
treated with immune checkpoint inhibitors,” said Hervé
Affagard, CEO and co-founder of MaaT Pharma. “In this context,
Nathalie will be instrumental in driving and expanding our
scientific innovation and preclinical drug development strategy. I
welcome Nathalie to the executive team and look forward to her
contributions as we pursue our mission to provide the benefits of
microbiome modulation to cancer patients.”
MaaT Pharma has established clinical proof of concept for its
high-richness, high-diversity, native, donor-derived MET-N
approach, with more than 140 patients treated in Europe to date in
haemato-oncology with its drug candidates MaaT013 (for the
treatment of aGvHD1) and MaaT033 (for the treatment of patients
receiving allo-HSCT2), with promising safety and efficacy results.
MaaT Pharma is now consolidating its second-generation drug
development platform, MET-C. Leveraging its gutPrint® AI3 suite and
groundbreaking ecosystem co-culture technology, MET-C allows the
design and manufacturing of indication-specific, donor-independent
“MaaT03X” candidates. The platform opens new opportunities for the
Company to address larger, and growing markets such as solid
tumors, as well as to broaden its indication focus and potentially
target other immune- and inflammatory-related diseases.
Nathalie Corvaïa, Ph.D. commented on the appointment
adding, “MaaT Pharma’s approach of leveraging the full
microbiome ecosystem to improve cancer treatment has the potential
to become a new pillar in cancer therapy. With an exciting
discovery pipeline and AI-powered engine, I am thrilled to join
MaaT Pharma to guide the development of its next generation of
therapies, to build the company’s momentum with the immuno-oncology
program and to expand its early-stage drug development in this
field.”
Prior to joining MaaT Pharma, Dr. Corvaïa was the Head of
Immuno-oncology Research at The Pierre Fabre Immunology Center
(CIPF) in France where she was responsible for the institute’s
research activities in immuno-oncology from early-stage product
discovery to Phase 1 entry, including GMP production of its
products including biologics and live products. In her previous
roles as Managing Director and Research Director, she led several
diverse research teams contributing to a growing pipeline of
products currently in preclinical and clinical trials in different
tumor indications. Dr. Corvaïa did her postdoctoral research in
cellular immunology at Novartis in Austria and obtained a PhD
degree in Cellular Immunology at St. Louis Hospital in Paris,
France. She has authored over 100 scientific publications and holds
several issued patents and is also an active member of the American
Association for Cancer Research (AACR).
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022 in Europe, a Phase 3 clinical trial for patients with
acute GvHD, following the achievement of its proof of concept in a
Phase 2 trial. Its powerful discovery and analysis platform,
gutPrint®, supports the development and expansion of its pipeline
by determining novel disease targets, evaluating drug candidates,
and identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is the first company
developing microbiome-based therapies listed on Euronext Paris
(ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
1 aGVHD = acute Graft-versus-Host Disease 2 Allo-HSCT =
Allogeneic hematopoietic stem cell transplantation 3 AI :
Artificial intelligence
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005754/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
prichaud@maat-pharma.com
Trophic Communications – Corporate and Medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89
2070 89831 maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 5 2023 まで 6 2023
Maat Pharma (EU:MAAT)
過去 株価チャート
から 6 2022 まで 6 2023